Cardiology

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

The ACC provides evidence-based guidance on improving vaccine uptake in vulnerable patients, addressing vaccine hesitancy, and improving overall vaccine access.

ESC 2025: The first global investigation of evidence for the potential positive connection is encouraging, but more research is needed to understand causality.

The FDA removed the prior requirement for a person who is already diagnosed with a cardiovascular disease.

Your daily dose of the clinical news you may have missed.

Shagun Bindlish, MD, board member of the American Diabetes Association, discusses challenges to diagnosing and treating venous disease in patients with obesity.

Vaginal estradiol is often prescribed as first-line therapy for genitourinary syndrome of menopause, making the findings supportive of current clinical practice.

Your daily dose of the clinical news you may have missed.

Updates to the 2017 guideline focus on new monitoring strategies, earlier intervention to reduce cognitive decline, improved perinatal care, and refined risk assessment.

RDX-002, an investigational, first-in-class therapeutic, significantly reduced weight regain after cessation of antiobesity treatment with semaglutide and tirzepatide.

A new study reveals that noninvasive LVEDP screening can enhance heart failure detection and improve patient outcomes in primary care settings.

The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.

Your daily dose of the clinical news you may have missed.

Adequate sleep tops the 4 elements most important to CV health after menopause, with blood pressure, glucose levels, and smoking status close behind.

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

Monu Khanna, MD, offers 3 takeaways for primary care: address obesity as root cause, reduce stigma, and explore new treatments to reduce cardiovascular risk.

Dr Khanna discusses how PCPs can use patient relationships to tailor lifestyle advice and manage obesity-related cardiometabolic disease.

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

These new FDA-approved drugs include treatments for migraine, chronic spontaneous urticaria, RSV, and more.

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.